Bioventix (BVXP)

 

BVXP Share PerformanceMore

52 week high2,950.0 09/10/17
52 week low26.0 15/11/17
52 week change 1,122.5 (82.99%)
4 week volume87,448 25/12/17

Latest NewsMore

Result of AGM

Bioventix plc (?Bioventix? or the ?Company?) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (?AGM?), all resolutions put to shareholders were duly passed. Prior to the AGM, Resolution 5 was withdrawn. For further information please contact: Bioventix plc Peter Harrison Chief Executive Officer Tel: 01252 728 001 finnCap L...

Director Deals - Bioventix Plc (BVXP)

Peter Harrison, Chief Executive Officer, sold 80,000 shares in the company on the 19th October 2017 at a price of 2425.00p. ...

Director Deals - Bioventix Plc (BVXP)

Ian Nicholson, Chairman, sold 5,000 shares in the company on the 19th October 2017 at a price of 2400.75p. The Director no...

Director/PDMR Shareholding

Bioventix plc (?Bioventix? or the ?Company?) Director/PDMR Shareholding Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (?Ordinary Shares?)...

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX 1b. Please indicate if the issuer is a non-UK issuer (please mark...

Broker Forecast - finnCap issues a broker note on Bioventix Plc

finnCap today reaffirms its corporate investment rating on Bioventix Plc (LON:BVXP) and set its price target at 2600p.

Bioventix pre-tax profits up 37%

Pre-tax profits at Bioventix rose by 37% to 5.7m in the year to the end of June. Revenues rose by 31% to 7.2m and were ahe...

Final Results

Bioventix plc (?Bioventix? or the ?Company?) Preliminary results for the year ended 30 June 2017 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2017. Highlights: ? Revenue up 31% to ?7.2...

Fundamental DataMore

P/E ratio25.685
EPS96.36
Dividend yield2.061 %

Latest discussion posts More

  • Re: AGM

    I know it,s a while ago Hardboybut did you attend AGM? Anything of interest. SM
    19-Jan-2018
    smilingmickey1
  • AGM

    Subject to weather I am hoping to go to the AGM on Thursday. Anyone else planning to be there?
    11-Dec-2017
    Hardboy
  • xd

    It's unusual to see a rise like that on a day of no news and the share going ex div
    26-Oct-2017
    Hardboy

Users' HoldingsMore

Users who hold Bioventix also hold..

Codes & Symbols

ISINGB00B4QVDF07
SymbolsBVXP, LSE:BVXP, BVXP.L, BVXP:LN, LON:BVXP, XLON:BVXP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account